Background: Structural or bulk osteochondral allograft transplantation for shoulder talar osteochondral lesions as a salvage procedure has demonstrated efficacy in several retrospective reviews. The purpose of this study was to evaluate prospectively patients who received fresh structural allograft transplantation to the talus. Methods: Prospective evaluation of a consecutive series of patients who underwent fresh structural allograft transplantation for an osteochondral lesion of the talus (OLT) was performed. Preoperative magnetic resonance imaging (MRI) and/or computed tomography (CT) and plain radiographs were obtained on all patients. The following patient-reported outcomes questionnaires were administered preoperatively and yearly after surgery: 100-mm visual analog scale (VAS) pain scale, American Orthopaedic Foot & Ankle Society (AOFAS) Ankle-Hindfoot Scale, Short Form 36 (SF-36), and the Short Musculoskeletal Functional Assessment (SMFA). Preoperative and postoperative radiographs were assessed for allograft incorporation and subsequent arthritis. Fourteen patients with an average age of 40 years (range, 18-69) and a mean followup of 55 months (range, 24-97) underwent structural fresh osteochondral allograft transplantation to the talar shoulder. Results: The average size of the OLT was 2269 mm 3 (range, 813-8366) based on CT imaging and 5797 mm 3 (range, 1136-12 489) based on MRI imaging. There was significant (P < .05) improvement in the VAS pain, AOFAS scale, SF-36, and SMFA scores. Five (36%) of the patients required additional surgery for pain and stiffness. Two patients had cartilage delamination and were considered treatment failures. Therefore, the success rate was 86% (12/14). Conclusion: Significant improvement in pain and function was achieved with structural allograft transplantation for large OLTs at midterm follow-up. This was a safe and effective treatment option in this small series for large OLTs. Level of Evidence: Level IV, prospective case series.
Article
Osteochondral lesions of the talus (OLTs) are defects of the articular cartilage of the talus and the underlying subchondral bone. 5 OLTs can be difficult to treat due to the poor intrinsic ability of cartilage to heal as well as the tenuous vascular supply to the talus. Grafting techniques such as osteochondral autograft transport system (OATS) and mosaicplasty have been described as viable treatment options for smaller lesions. 2, 15 However, in the setting of either a salvage procedure or a large lesion (>1.5 cm 2 area) with cystic changes to the subchondral bone, fresh structural osteochondral allograft is a viable procedure demonstrating early promising results. 1, 12 However, a subset of OLTs are not readily amenable to traditional techniques. These are typically large lesions involving a substantial amount of the weightbearing portion of the talar dome and either the medial or lateral articular surface. Their size, 2-dimensional articular cartilage geometry, 3-dimensional bony geometry, and loss of the medial or lateral articular buttress may preclude them from treatment with current cylindrical osteochondral autograft or cartilage transplantation techniques. Several studies have described the use of fresh structural or bulk allograft transplantation for OLTs, with the majority being retrospective. 1, 7, 10, 11, 14, 20 A few have been prospective evaluations. 4, 13 Despite the increasing number of successful reports about fresh structural allograft The purpose of this study was to follow prospectively a cohort of patients who underwent fresh bulk talus allograft transplantation. Our hypothesis was that large, fresh geometrically contoured talar allografts would improve pain and function in patients with large osteochondral lesions of the talar shoulder.
Methods

Study Design and Preoperative Evaluation
This is a prospective consecutive series of patients who underwent fresh osteochondral allograft transplantation for osteochondral lesions of the talar shoulder at our institution between 2010 and 2014. All patients failed previous operative or nonoperative treatment for lesions too large to be adequately treated by alternative techniques. A minimum follow-up of 2 years was required to be included in this report. Institutional review board approval was obtained prior to initiation of this study.
Fourteen patients with a mean age of 40 years (range, 18-69) were included in this study. There were 8 men and 6 women with a mean follow-up of 55 months (range, 24-97). Nine patients reported a history of ankle trauma while the cause of the OLT in the remaining 5 patients was unknown. The mean duration of symptoms prior to talus allograft was 8.9 years (range, 0.5-25). Thirteen lesions were located on the medial shoulder while 1 lesion was located on the lateral talus shoulder. Ten patients underwent prior operative intervention, including arthroscopic marrow stimulation. Four of these 10 patients underwent a second operative procedure prior to allograft transplantation. The remaining 4 patients presented with lesions deemed too large to treat with microfracture or other cartilage procedure.
Preoperative assessment included physical examination, weightbearing radiographs, computed tomography (CT) scan and/or magnetic resonance imaging (MRI), and administration of a 100-mm visual pain scale, the American Orthopaedic Foot & Ankle Society (AOFAS) AnkleHindfoot Scale, the Short Form 36 (SF-36), and the Short Musculoskeletal Functional Assessment (SMFA).
The required size of the donor talus was calculated from the radiographs and CT scan. The patients were placed on a waiting list and treated with supportive modalities until the fresh graft was available. All osteochondral allografts were obtained from nationally recognized suppliers who comply with the procurement and processing guidelines of the US Food and Drug Administration, the American Association of Tissue Banks, and Clinical Laboratory Improvement Amendments. 19 In addition, all grafts were considered fresh, meaning they were never frozen and implanted within the tissue banks' expiration window. A general timeline of graft preparation was as follows. Once a donor was identified, the talus was harvested under sterile conditions within 24 hours of death. Next, the allograft underwent disease testing and sterility culturing for approximately 14 days. During this time, the donor's medical chart was reviewed for factors that might lead to an unacceptable graft (eg, high-risk behavior). If the graft passed, proprietary processing techniques were performed and the graft was packaged for shipping (~day 21). The graft was maintained at 2°C to 4°C throughout this process. The graft typically arrived at the hospital in 1 day. Prior to shipping, the surgeon was notified of graft approval and contacted the patient. Patient and surgeon availability then ultimately affected the timing of allograft implantation, but typically the delay was less than 1 week. No age, sex, tissue, or blood type matching was performed. Serum anti-human leukocyte antigen (HLA) antibodies were not measured.
Operative Technique
Patients in this study underwent partial talus shoulder replacement through a medial or lateral osteotomy or a complete talus shoulder replacement (referred to as a hemitalus replacement) through an anterior arthrotomy ( Figure  1 ). In all cases, the talar shoulder lesion was identified and debrided to stable articular cartilage margins and bleeding cancellous bone. The edges were cut square with a fine saw to allow for correct geometric fitting of the allograft. The dimensions of the lesion were marked onto the corresponding location of the fresh allograft talus. The graft was then cut with oscillating and reciprocating saws. The graft was stabilized in the ankle with 1 or 2 countersunk titanium mini-fragment (2.0-mm) headed cancellous screws. The medial or lateral osteotomy was repaired with standard internal fixation. Intraoperative fluoroscopy was performed to confirm the placement and fit of the graft and malleolar osteotomy. Tisseel was used to seal the interval between native cartilage and the allograft cartilage.
Postoperatively, the ankles were immobilized for 6 weeks in a nonweightbearing cast. They were then transitioned into controlled-ankle motion walking boot for an additional 6 weeks with progression to full weightbearing over that time.
Postoperative Evaluation
Yearly, all patients underwent a physical examination and weightbearing radiographs. In addition, at each postoperative visit, all patients were administered the same questionnaires as previously described. All postoperative imaging, performed at the most recent follow-up, was reviewed for graft collapse, graft nonunion, osteotomy nonunion, or loss of ankle joint space. If graft failure was a concern, a CT scan was obtained in addition to weightbearing radiographs.
Failure of operation was defined as persistent painful symptoms requiring a subsequent procedure with screw cut out, graft loosening, or graft delamination.
Statistical Analysis
Statistical analysis was performed on preoperative and postoperative outcome measures and OLT size using a paired t test. Chi-square analysis was performed when comparing characteristics of partial vs hemi-talus allografts. Statistical significance was set at P < .05.
Results
Patient and Allograft Demographics
Based on preoperative assessment of radiographs, CT scan, and MRI, preoperative planning for the size of the allograft was measured to determine if a hemitalar or partial talar allograft was adequate to treat the entirety of the pathology. Seven patients underwent talus allograft transplantation through a medial (6) or lateral (1) malleolus osteotomy. These grafts were partial shoulder allografts. The other 7 patients underwent talus allograft through an anterior incision without associated malleolus osteotomy. The entire shoulder in the anteroposterior direction and approximately one-third to one-half of the medial to lateral talar dome was replaced, and these were considered hemi-talus allografts. The approach was based on the size of the lesion and the surgeon's discretion.
Outcomes Measures
A summary of outcome measure scores is presented in Table 1 . There was a significant decrease in pain and significant improvement in all functional outcome measures and submeasures (some submeasure data not shown). All patients stated they would have the procedure again. 
Radiographic Assessments
The mean size of the OLT based on CT evaluation was 2269 mm 3 (range, 813-8366), whereas the mean size of the OLT based on MRI evaluation was 5797 mm 3 (range, 1136-12 489). Postoperative radiolucencies were evaluated. There were 3 lucencies noted. All were along the sagittal plane edge of the interface of the graft with the main body of the talus (Figure 2) . None of the lucencies were seen in failed allografts. A change in joint space from the first weightbearing radiographs to most recent follow-up was evaluated. Three patients demonstrated progression of joint space narrowing at the most recent follow-up; 1 of these was a treatment failure.
Additional Surgeries and Graft Survival
Five (36%) of the patients required additional surgery for symptoms of pain and stiffness. All surgeries were ankle arthroscopy with debridement and removal of the screw(s) used to secure the graft. One of these patients also had medial malleolus hardware removed at the same time. Three of these second-look patients had stable grafts without chondral damage. One graft was loose and had cartilage delamination. The patient developed progressive arthritis and is awaiting an ankle replacement. Another graft demonstrated cartilage delamination. This patient had continued pain and progression of arthritis and was converted to an ankle replacement. Therefore, the overall survival rate for allografts was 86% (12/14).
Comparison of Partial vs Hemi-Talus Allografts
A comparison of radiographic parameters, additional procedures, and failures between partial and hemi-talus allografts is shown in Table 2 . There were no significant differences between the 2 types of allografts with the numbers available. 
Discussion
The treatment of OLTs involving the talar shoulder remains a challenge. This study demonstrated successful outcomes with the use of a partial or hemi-talus allograft replacement ( Figure 3) . The patient population in the present study demonstrated significantly decreased pain and increased functional improvement with minimal radiographic joint space changes at a mean follow-up of greater than 4 years using this procedure. There have been several reports detailing the success of fresh bulk talus allografts. In one of the earliest reports on this technique, Gross et al 11 reported on 9 patients who underwent fresh osteochondral allograft transplantation. At a mean follow-up of 11 years, 6 grafts remained in situ. The 3 failed allografts demonstrated radiographic and intraoperative evidence of fragmentation or resorption, and these patients went on to ankle fusion at 36, 56, and 83 months following allograft surgery. Standardized outcomes measures for comparison were not used in that study. The relatively late conversion to arthrodesis indicates the need for long-term monitoring of patients with osteochondral allografts but also potentially indicates the robustness of the allografts.
More recently, Raikin 20 reported on 15 patients who underwent bulk fresh osteochondral allografting for largevolume cystic lesions of the talus. The mean volume of the cystic lesions was 6059 mm 3 . At a mean follow-up of 4.5 years, the mean AOFAS ankle-hindfoot score was 83 points. Only 2 patients had grafts that failed and went on to have an ankle arthrodesis. Some form of graft collapse, graft resorption, or joint space narrowing was seen in all patients.
In the present series, we performed the allografts either from a medial malleolus osteotomy (partial allograft) or through a direct anterior approach (hemi-allograft). Although there were 7 of each allograft, the approach and graft type were not randomized. We found no significant differences between the 2 types of allografts in our series, but we are underpowered. However, it has become our preference to perform hemi-allografts as there is no risk for medial or lateral malleolus nonunion or potential painful hardware.
While the use of fresh allograft transplantation for the treatment of OLTs has demonstrated success, several aspects about the technique should be discussed. It is important to mention differences in the radiographically measured lesion volume and the true volume of the lesion or the allograft volume. We routinely obtain either an MRI or CT scan, and sometimes both, to aid in the determination of the size of the lesion to ascertain whether allograft transplantation is the most appropriate treatment and to help with preoperative planning. We realize that this is still an estimated volume. MRI often overestimates the size of the lesion secondary to surrounding bone marrow edema. However, an estimated size of the OLT is still very helpful. The basis of allograft transplantation is to provide viable chondrocytes. Fresh osteochondral allografts have been shown to contain viable chondrocytes for at least up to 17 years after transplantation. 6, 18 On the contrary, using frozen osteochondral allografts, Enneking and Campanacci 8 and Enneking and Mindell 9 demonstrated absence of viable chondrocytes and cartilage breakdown as early as 1 year after transplantation. Although these studies were not performed in the talus, we prefer to use fresh osteochondral allografts over cryopreserved grafts. However, it is important to note that chondrocyte viability decreases with time in fresh allografts. Williams et al 21 reported a significant decrease in viable chondrocytes of human fresh osteochondral allografts by day 28. However, at day 28, the mean percentage of remaining viable chondrocytes was still 70% of the starting amount. We attempted to perform the transplantation as soon as the allograft was released, but many patient, surgeon, and hospital factors ultimately dictated the timing of the procedure.
As with any transplantation, disease transmission in osteochondral allografting remains a concern. The current estimated risk of human immunodeficiency virus (HIV) transmission in allograft tissue is 1 in 1 million. 19 There have been 3 reported cases of HIV transmission, 2 cases of hepatitis C virus transmission, and 1 case of hepatitis B virus transmission in allograft tissue. 19 We are unaware of any instances of disease transmission in our patient population. We do counsel our patients about the risks and benefits of receiving allograft tissue.
The most important concern about the use of talus allografts is the fact that it is still considered experimental by many insurance companies despite numerous reports demonstrating its efficacy. In fact, the following excerpt was taken from the Aetna website: "Aetna considers osteochondral allograft of the talus experimental and investigational because there are unanswered questions regarding the clinical outcomes of this approach when compared with ankle arthrodesis, especially in terms of pain, disability, functionality and durability." 17 While we do agree that the use of talus allografts has not been compared with ankle arthrodesis, there is really no need to perform this comparison. We feel that large but focal OLTs, especially in young patients, should not be treated with ankle arthrodesis especially given the results herein as well as the numerous additional reports on the success of talus allografts. We do, however, agree that additional long-term studies are needed to determine the durability of fresh talus allografts.
Conclusion
Osteochondral lesions of the talar shoulder without widespread joint disease present a treatment challenge. We present midterm pain, functional, and radiographic data to support the use of structural talar allograft transplantation for large OLTs. This procedure afforded significant pain relief and improvement in patient-reported outcomes and did not preclude repeat allograft transplantation, conversion to total ankle arthroplasty, or ankle arthrodesis.
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